Dopamine D2 and angiotensin II type 1 receptors form functional heteromers in rat striatum

Biochemical Pharmacology

Volumn 96, Issue 2, 2015, Pages 131-142

  Martinez Pinilla E ^a   Rodriguez Perez A I ^b,d   Navarro, G ^c,d   Aguinaga, D ^c,d   Moreno, E ^c,d   Lanciego, J L ^a,d   Labandeira Garcia J L ^b,d   Franco, R ^c,d  

^a UNIVERSITY OF NAVARRA   (Spain)

^b Universidade de Santiago de Compostela and Instituto de Investigación Sanitaria de Santiago de Compostela   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED SOBRE ENFERMEDADES NEURODEGENERATIVAS CIBERNED   (Spain)

Author keywords

Basal ganglia; BRET; Calcium release; cAMP; GPCR heteromerization

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANGIOTENSIN 1 RECEPTOR; BETA ARRESTIN; CALCIUM; CANDESARTAN; COMPLEMENTARY DNA; CYCLIC AMP; DOPAMINE 2 RECEPTOR; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 1; MULTIPROTEIN COMPLEX; RETINA S ANTIGEN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BIOLUMINESCENCE RESONANCE ENERGY TRANSFER; BRAIN LEVEL; BRAIN SLICE; CALCIUM TRANSPORT; CONCENTRATION CAMP; CORPUS STRIATUM; DOPAMINERGIC TRANSMISSION; FEMALE; GENETIC TRANSFECTION; NERVE CELL CULTURE; NONHUMAN; PRIMARY CULTURE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; HEK293 CELL LINE; HUMAN; METABOLISM; PHOSPHORYLATION; SPRAGUE DAWLEY RAT;

ANIMALS; ARRESTINS; CORPUS STRIATUM; CYCLIC AMP; HEK293 CELLS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MULTIPROTEIN COMPLEXES; PHOSPHORYLATION; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTORS, DOPAMINE D2;

EID: 84930571439     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2015.05.006     Document Type: Article

References (63)

1. R.L. Albin, A.B. Young, and J.B. Penney The functional anatomy of basal ganglia disorders Trends Neurosci. 12 1989 366 375
2. M.R. DeLong Primate models of movement disorders of basal ganglia origin Trends Neurosci. 13 1990 281 285
3. M. Herrera-Marschitz, and U. Ungerstedt The dopamine-gamma aminobutyric acid interaction in the striatum of the rat is differently regulated by dopamine D-1 and D-2 types of receptor: evidence obtained with rotational behavioural experiments Acta Physiol. Scand. 129 1987 371 380
4. H.R. Brunner, P. Chang, R. Wallach, J.E. Sealey, and J.H. Laragh Angiotensin II vascular receptors: their avidity in relationship to sodium balance, the autonomic nervous system, and hypertension J. Clin. Invest. 51 1972 58 67
5. N.E. Sirett, J.J. Bray, and J.I. Hubbard Localization of immunoreactive angiotensin II in the hippocampus and striatum of rat brain Brain Res. 217 1981 405 411
6. J.M. Saavedra Brain angiotensin II: new developments, unanswered questions and therapeutic opportunities Cell Mol. Neurobiol. 25 2005 485 512
7. M.I. Phillips, and E.M. de Oliveira Brain renin angiotensin in disease J. Mol. Med. 86 2008 715 722
8. R.L. Stornetta, C.L. Hawelu-Johnson, P.G. Guyenet, and K.R. Lynch Astrocytes synthesize angiotensinogen in brain Science 242 1988 1444 1446
9. A. Milsted, B.P. Barna, R.M. Ransohoff, K.B. Brosnihan, and C.M. Ferrario Astrocyte cultures derived from human brain tissue express angiotensinogen mRNA Proc. Natl. Acad. Sci. U.S.A. 87 1990 5720 5723
10. A. Kumar, A. Rassoli, and M.K. Raizada Angiotensinogen gene expression in neuronal and glial cells in primary cultures of rat brain J. Neurosci. Res. 19 1988 287 290
11. W.G. Thomas, K.J. Greenland, T.A. Shinkel, and C. Sernia Angiotensinogen is secreted by pure rat neuronal cell cultures Brain Res. 588 1992 191 200
12. K. Hermann, W. McDonald, T. Unger, R.E. Lang, and D. Ganten Angiotensin biosynthesis and concentrations in brain of normotensive and hypertensive rats J. Physiol. 79 1984 471 480
13. R. Valenzuela, P. Barroso-Chinea, A. Muñoz, B. Joglar, B. Villar-Cheda, J.L. Lanciego, and J.L. Labandeira-Garcia Location of prorenin receptors in primate substantia nigra: effects on dopaminergic cell death J. Neuropathol. Exp. Neurol. 69 2010 1130 1142
14. J.A. Luetscher, F.B. Kraemer, D.M. Wilson, H.C. Schwartz, and M. Bryer-Ash Increased plasma inactive renin in diabetes mellitus. A marker of microvascular complications N. Engl. J. Med. 312 1985 1412 1417
15. J. Rodriguez-Pallares, P. Rey, J.A. Parga, A. Munoz, M.J. Guerra, and J.L. Labandeira-Garcia Brain angiotensin enhances dopaminergic cell death via microglial activation and NADPH-derived ROS Neurobiol. Dis. 31 2008 58 73
16. P. Garrido-Gil, R. Valenzuela, B. Villar-Cheda, J.L. Lanciego, and J.L. Labandeira-Garcia Expression of angiotensinogen and receptors for angiotensin and prorenin in the monkey and human substantia nigra: an intracellular renin-angiotensin system in the nigra Brain Struct. Funct. 218 2013 373 388
17. P.B. Timmermans, P.C. Wong, A.T. Chiu, W.F. Herblin, P. Benfield, D.J. Carini, R.J. Lee, R.R. Wexler, J.A. Saye, and R.D. Smith Angiotensin II receptors and angiotensin II receptor antagonists Pharmacol. Rev. 45 1993 205 251
18. J.K. Wamsley, W.F. Herblin, M.E. Alburges, and M. Hunt Evidence for the presence of angiotensin II-type 1 receptors in brain Brain Res. Bull. 25 1990 397 400
19. T.J. Murphy, R.W. Alexander, K.K. Griendling, M.S. Runge, and K.E. Bernstein Isolation of a cDNA encoding the vascular type-1 angiotensin II receptor Nature 351 1991 233 236
20. K. Sasaki, Y. Yamano, S. Bardhan, N. Iwai, J.J. Murray, M. Hasegawa, Y. Matsuda, and T. Inagami Cloning and expression of a complementary DNA encoding a bovine adrenal angiotensin II type-1 receptor Nature 351 1991 230 233
21. B.P. Rowe, D.L. Saylor, and R.C. Speth Analysis of angiotensin II receptor subtypes in individual rat brain nuclei Neuroendocrinology 55 1992 563 573
22. K. Sandberg, H. Ji, A.J. Clark, H. Shapira, and K.J. Catt Cloning and expression of a novel angiotensin II receptor subtype J. Biol. Chem. 267 1992 9455 9458
23. T.A. Jenkins, A.M. Allen, S.Y. Chai, D.P. MacGregor, G. Paxinos, and F.A. Mendelsohn Interactions of angiotensin II with central dopamine Adv. Exp. Med. Biol. 396 1996 93 103
24. J.L. Labandeira-Garcia, P. Garrido-Gil, J. Rodriguez-Pallares, R. Valenzuela, A. Borrajo, and A.I. Rodriguez-Perez Brain renin-angiotensin system and dopaminergic cell vulnerability Front. Neuroanat. 8 2014 67
25. J.W. Wright, and J.W. Harding Importance of the brain Angiotensin system in Parkinson's disease Parkinsons Dis. 2012 860923
26. P.K. Sonsalla, C. Coleman, L.Y. Wong, S.L. Harris, J.R. Richardson, B.S. Gadad, W. Li, and D.C. German The angiotensin converting enzyme inhibitor captopril protects nigrostriatal dopamine neurons in animal models of parkinsonism Exp. Neurol. 250 2013 376 383
27. S. Sathiya, V. Ranju, P. Kalaivani, R.J. Priya, H. Sumathy, A.G. Sunil, and C.S. Babu Telmisartan attenuates MPTP induced dopaminergic degeneration and motor dysfunction through regulation of α-synuclein and neurotrophic factors (BDNF and GDNF) expression in C57BL/6J mice Neuropharmacology 73 2013 98 110
28. A. Muñoz, P. Garrido-Gil, A. Dominguez-Meijide, and J.L. Labandeira-Garcia Angiotensin type 1 receptor blockage reduces l-dopa-induced dyskinesia in the 6-OHDA model of Parkinson's disease. Involvement of vascular endothelial growth factor and interleukin-1β Exp. Neurol. 261 2014 720 732
29. S.H. Padia, B.A. Kemp, N.L. Howell, S.R. Keller, J.J. Gildea, and R.M. Carey Mechanisms of dopamine D(1) and angiotensin type 2 receptor interaction in natriuresis Hypertension 59 2012 437 445
30. J.L. Labandeira-Garcia, J. Rodriguez-Pallares, A.I. Rodriguez-Perez, P. Garrido-Gil, B. Villar-Cheda, R. Valenzuela, and M.J. Guerra Brain angiotensin and dopaminergic degeneration: relevance to Parkinson's disease Am. J. Neurodegener. Dis. 1 2012 226 244
31. J.L. Labandeira-Garcia, J. Rodriguez-Pallares, A. Dominguez-Meijide, R. Valenzuela, B. Villar-Cheda, and A.I. Rodriguez-Perez Dopamine-angiotensin interactions in the basal ganglia and their relevance for Parkinson's disease Mov. Disord. 28 2013 1337 1342
32. D. Li, L. Scott, S. Crambert, S. Zelenin, A.C. Eklof, L. Di Ciano, F. Ibarra, and A. Aperia Binding of losartan to angiotensin AT1 receptors increases dopamine D1 receptor activation J. Am. Soc. Nephrol. 23 2012 421 428
33. C. Zeng, L.D. Asico, X. Wang, U. Hopfer, G.M. Eisner, R.A. Felder, and P.A. Jose Angiotensin II regulation of AT1 and D3 dopamine receptors in renal proximal tubule cells of SHR Hypertension 41 2003 724 729
34. C. Zeng, Y. Luo, L.D. Asico, U. Hopfer, G.M. Eisner, R.A. Felder, and P.A. Jose Perturbation of D1 dopamine and AT1 receptor interaction in spontaneously hypertensive rats Hypertension 42 2003 787 792
35. C. Zeng, Z. Yang, Z. Wang, J. Jones, X. Wang, J. Altea, A.J. Mangrum, U. Hopfer, D.R. Sibley, G.M. Eisner, R.A. Felder, and P.A. Jose Interaction of angiotensin II type 1 and D5 dopamine receptors in renal proximal tubule cells Hypertension 45 2005 804 810
36. J. Hradsky, M. Mikhaylova, A. Karpova, M.R. Kreutz, and W. Zuschratter Super-resolution microscopy of the neuronal calcium-binding proteins Calneuron-1 and Caldendrin. Calneuron-1 and Caldendrin Methods Mol. Biol. 963 2013 147 169
37. G. Navarro, M.S. Aymerich, D. Marcellino, A. Cortés, V. Casadó, J. Mallol, E.I. Canela, L. Agnati, A.S. Woods, K. Fuxe, C. Lluis, J.L. Lanciego, S. Ferre, and R. Franco Interactions between calmodulin, adenosine A2A, and dopamine D2 receptors J. Biol. Chem. 284 2009 28058 28068
38. T-W. Chen, T.J. Wardill, Y. Sun, S.R. Pulver, S.L. Renninger, A. Baohan, E.R. Schreiter, R.A. Kerr, M.B. Orger, V. Jayaraman, L. Looger, K. Svoboda, and D.S. Kim Ultra-sensitive fluorescent proteins for imaging neuronal activity Nature 499 2013 295 300
39. E. Lazartigues, S.M. Dunlay, A.K. Loihl, P. Sinnayah, J.A. Lang, J.J. Espelund, C.D. Sigmund, and R.L. Davisson Brain-selective overexpression of angiotensin (AT1) receptors causes enhanced cardiovascular sensitivity in transgenic mice Circul. Res. 90 2002 617 624
40. A.I. Rodriguez-Perez, R. Valenzuela, B. Villar-Cheda, M.J. Guerra, J.L. Lanciego, and J.L. Labandeira-Garcia Estrogen and angiotensin interaction in the substantia nigra. Relevance to postmenopausal Parkinson's disease Exp. Neurol. 224 2010 517 526
41. I.M. Bird, J. Zheng, J.M. Cale, and R.R. Magness Pregnancy induces an increase in angiotensin II type-1 receptor expression in uterine but not systemic artery endothelium Endocrinology 138 1997 490 498
42. P. Trifilieff, M.L. Rives, E. Urizar, R.A. Piskorowski, H.D. Vishwasrao, J. Castrillon, C. Schmauss, M. Slättman, M. Gullberg, and J.A. Javitch Detection of antigen interactions ex vivo by proximity ligation assay: endogenous dopamine D2-adenosine A2A receptor complexes in the striatum Biotechniques 51 2011 111 118
43. V.A. Boundy, R.R. Luedtke, R.P. Artymyshyn, T.M. Filtz, and P.B. Molinoff Development of polyclonal anti-D2 dopamine receptor antibodies using sequence-specific peptides Mol. Pharmacol. 43 1993 666 676
44. H. Wang, and V.M. Pickel Dopamine D2 receptors are present in prefrontalcortical afferents and their targets in patches of the rat caudate-putamen nucleus J. Comp. Neurol. 442 2002 392 404
45. S. Ferre, R. Baler, M. Bouvier, M.G. Caron, L.A. Devi, T. Durroux, K. Fuxe, S.R. George, J.A. Javitch, M.J. Lohse, K. Mackie, G. Milligan, K.D. Pfleger, J.P. Pin, N.D. Volkow, M. Waldhoer, A.S. Woods, and R. Franco Building a new conceptual framework for receptor heteromers Nat. Chem. Biol. 5 2009 131 134
46. S. Gonzalez, D. Moreno-Delgado, E. Moreno, K. Perez-Capote, R. Franco, J. Mallol, A. Cortes, V. Casado, C. Lluis, J. Ortiz, S. Ferre, E. Canela, and P.J. McCormick Circadian-related heteromerization of adrenergic and dopamine D(4) receptors modulates melatonin synthesis and release in the pineal gland PLoS Biol. 10 2012 e1001347
47. N.A. Balenga, E. Martinez-Pinilla, J. Kargl, R. Schroder, M. Peinhaupt, W. Platzer, Z. Balint, M. Zamarbide, I. Dopeso-Reyes, A. Ricobaraza, J.M. Perez-Ortiz, E. Kostenis, M. Waldhoer, A. Heinemann, and R. Franco Heteromerization of GPR55 and cannabinoid CB receptors modulates signaling Br. J. Pharmacol. 171 2014 5387 5406
48. L. Callen, E. Moreno, P. Barroso-Chinea, D. Moreno-Delgado, A. Cortes, J. Mallol, V. Casado, J.L. Lanciego, R. Franco, C. Lluis, E.I. Canela, and P.J. McCormick Cannabinoid receptors CB1 and CB2 form functional heteromers in brain J. Biol. Chem. 287 2012 20851 20865
49. E. Martinez-Pinilla, I. Reyes-Resina, A. Onatibia-Astibia, M. Zamarbide, A. Ricobaraza, G. Navarro, E. Moreno, I.G. Dopeso-Reyes, S. Sierra, A.J. Rico, E. Roda, J.L. Lanciego, and R. Franco CB and GPR55 receptors are co-expressed and form heteromers in rat and monkey striatum Exp. Neurol. 261 2014 44 52
50. J. Bonaventura, A.J. Rico, E. Moreno, S. Sierra, M. Sanchez, N. Luquin, D. Farre, C.E. Muller, E. Martinez-Pinilla, A. Cortes, J. Mallol, M.T. Armentero, A. Pinna, E.I. Canela, C. Lluis, P.J. McCormick, J.L. Lanciego, and V. Casado Franco R. l-DOPA-treatment in primates disrupts the expression of A2A adenosine-CB1 cannabinoid-D2 dopamine receptor heteromers in the caudate nucleus Neuropharmacology 79 2014 90 100
51. O. Soderberg, K.J. Leuchowius, M. Gullberg, M. Jarvius, I. Weibrecht, L.G. Larsson, and U. Landegren Characterizing proteins and their interactions in cells and tissues using the in situ proximity ligation assay Methods 45 2008 227 232
52. A.M. Allen, I. Moeller, A. Jenkins, J. Zhuo, G.P. Aldred, S.Y. Chai, and F.A.O. Mendelsohn Angiotensin receptors in the nervous system Brain Res. Bull. 47 1998 17 18
53. A.M. Allen, D.P. MacGregor, S.Y. Chai, G.A. Donnan, S. Kaczymarzyk, K. Richardson, R. Kalnins, J. Ireton, and F.A.O. Mendelsohn Angiotensin II receptor binding associated with nigrostriatal dopaminergic neurons in human basal ganglia Ann. Neurol. 32 1992 339 344
54. B. Joglar, J. Rodriguez-Pallares, A.I. Rodríguez-Perez, P. Rey, M.J. Guerra, and J.L. Labandeira-Garcia The inflammatory response in the MPTP model of Parkinson's disease is mediated by brain angiotensin: relevance to progression of the disease J. Neurochem. 109 2009 656 669
55. F.A.O. Mendelsohn, T.A. Jenkins, and S.F. Berkovic Effects of angiotensin II on dopamine and serotonin turnover in the striatum of conscious rat Brain Res. 613 1993 221 229
56. D.C. Brown, L.J. Steward, J. Ge, and N.M. Barnes Ability of angiotensin II to modulate striatal dopamine release via AT1 receptor in vitro and in vivo Br. J. Pharmacol. 18 1996 414 420
57. B. Villar-Cheda, J. Rodríguez-Pallares, A. Muñoz, R. Valenzuela, M.J. Guerra, O.C. Baltatu, and J.L. Labandeira-Garcia Nigral and striatal regulation of angiotensin receptor expression by dopamine and angiotensin in rodents: implications for progression of Parkinson's disease Eur. J. Neurosci. 32 2010 1695 1706
58. B. Villar-Cheda, A. Dominguez-Meijide, R. Valenzuela, N. Granado, R. Moratalla, and J.L. Labandeira-Garcia Aging-related dysregulation of dopamine and angiotensin receptor interaction Neurobiol. Aging 35 2014 1726 1738
59. A.J. Rashid, C.H. So, M.M. Kong, T. Furtak, M. El-Ghundi, R. Cheng, B.F. O'Dowd, and S.R. George D1-D2 dopamine receptor heterooligomers with unique pharmacology are coupled to rapid activation of Gq/11 in the striatum Proc. Natl. Acad. Sci. U.S.A. 104 2007 654 659
60. M. Orru, J. Bakešová, M. Brugarolas, C. Quiroz, V. Beaumont, S.R. Goldberg, C. Lluís, A. Cortés, V. FrancoR. Casadó, E.I. Canela, and S. Ferré Striatal pre- and postsynaptic profile of adenosine A(2A) receptor antagonists PLoS One 6 2011 e16088
61. K.S. Thakur, A. Prakash, R. Bisht, and P.K. Bansal Beneficial effect of candesartan and lisinopril against haloperidol-induced tardive dyskinesia in rat J. Renin Angiotensin Aldosterone Syst. 2014 10.1177/1470320313515038
62. H. Itoh Drug-induced tardive dyskinesia Curr. Dev. Psychopharmacol. 6 1981 93 126
63. M. Ayehu, T. Shibre, B. Milkias, and A. Fekadu Movement disorders in neuroleptic-naïve patients with schizophrenia spectrum disorders BMC Psychiatry 4 2014 280